BSE filing, NSE: ASTRAZEN. Summary written from the filing by ALFA Finder's alert engine.
AstraZeneca Pharma India Ltd: key numbers
- Share price
- ₹6,290.00
- Market cap
- ₹15,725 Cr
- Revenue (annual)
- ₹2,276 Cr
- Net profit (annual)
- ₹187.5 Cr
- P/E (TTM)
- 92.7×Sector 46.1×
- Promoter holding
- 75.00%+0.00% QoQ
- FII holding
- 2.64%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from AstraZeneca Pharma India Ltd
All →AstraZeneca Pharma India Capacity Expansion
AstraZeneca Pharma India inaugurated a new corporate office in Mumbai, covering 25,600 sq ft. This expansion strengthens the company's commercial operations and footprint in India.
- office space
- 25600.0 sq ft
AstraZeneca Pharma India Annual General Meeting
AstraZeneca Pharma India Ltd declared the voting results of its postal ballot, confirming the appointment and designation change of certain non-executive directors.
AstraZeneca Pharma India Other Announcement
NSE Sustainability Ratings and Analytics assigned AstraZeneca Pharma India an ESG rating of 73 for FY 2025-26. The rating was independently prepared without company engagement.
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma India Limited received an order from the ROC, Bengaluru, imposing a total penalty of ₹0.03 Crore for a delayed filing. The company is evaluating next steps.
- Value
- ₹0.03 Cr
- From
- Registrar of Companies, Bengaluru, Karnataka
AstraZeneca Pharma India Legal & Regulatory
AstraZeneca Pharma disclosed a ₹1.88 lakh penalty from the Registrar of Companies due to a delay in filing Form MR-2.
- Value
- ₹0.02 Cr
AstraZeneca Pharma India Management Change
AstraZeneca Pharma India's Dr. Sandeep Arora resigned as Director, Medical Affairs, effective September 15, 2026. The company is seeking a suitable replacement for the position.
Other other announcement announcements
All →Infronics Systems Other Announcement
Infronics Systems appointed R & A Associates as Secretarial Auditor for FY 2026-27. This is a routine statutory appointment with no financial impact.
- Execution
- FY 2026-27
Onix Solar Energy Other Announcement
Onix Solar Energy's monitoring agency reports its rights issue proceeds are fully utilised. The report covers the quarter ended 30 September 2026.
Steamhouse India Other Announcement
Steamhouse India's Reg 32 statement confirms no deviation in IPO fund utilisation from prospectus objects for the quarter ended September 30, 2026. It also discloses a rectified issue-expense figure reallocating Rs 53.5 million to general corporate purposes.
Pine Labs Other Announcement
Pine Labs Limited filed CARE Ratings' Monitoring Agency Report for the quarter ended September 30, 2026, on its IPO proceeds. The report shows no deviation from objects and no major deviations.
Sihora Industries Other Announcement
Sihora Industries reported IPO proceeds utilisation of Rs.983.87 lakh of Rs.1,056 lakh raised, to September 2026. Shareholders approved the object deviation on 17 August 2026.
Titan Company Other Announcement
Titan's employee stock option trust transferred 19,385 shares worth Rs.8.40 Crore to eligible employees after PSU exercise. The off-market transfer was disclosed under PIT Reg 7(2).
- Value
- ₹8.40 Cr